抑制肥大细胞:尼达尼布抗纤维化作用的新机制
该研究探讨肥大细胞在特发性肺纤维化(IPF)中的作用,并比较尼达尼布与吡非尼酮对肥大细胞功能的影响。结果显示IPF肺组织中肥大细胞显著增多,与基线肺功能(FVC)负相关、与成纤维细胞灶数量正相关;尼达尼布(而非吡非尼酮)可抑制干细胞因子诱导的肥大细胞存活与活化,并在博来霉素大鼠模型中减少肺肥大细胞。
要点
- IPF肺组织中肥大细胞显著增多,与基线FVC负相关、与成纤维细胞灶数量正相关。
- 尼达尼布抑制SCF诱导的肥大细胞存活与活化,吡非尼酮无此作用。
- 尼达尼布在博来霉素大鼠模型中减少肺肥大细胞并影响高组织密度频率。
核心结论
- 尼达尼布通过抑制肥大细胞存活与活化,提供了一种抗纤维化的新机制。
研究设计与样本
- 研究纳入人IPF肺组织与体外共培养实验,并使用博来霉素大鼠肺纤维化模型。
主要发现
- IPF肺组织中肥大细胞显著升高,且与基线肺功能(FVC)呈负相关。
- 肥大细胞数量与成纤维细胞灶数量正相关,并在成纤维细胞灶周围区域增多。
- 共培养研究证实肥大细胞与成纤维细胞交互作用参与纤维化。
- 尼达尼布而非吡非尼酮抑制重组干细胞因子(SCF)诱导的肥大细胞存活。
- 尼达尼布抑制人成纤维细胞介导的肥大细胞存活,并阻断SCF刺激的ckit磷酸化及下游增殖与细胞因子释放。
临床怎么用
- 提示尼达尼布抗纤维化作用部分通过抑制肥大细胞存活与活化实现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease which presents a grave prognosis for diagnosed patients. Nintedanib (a triple tyrosine kinase inhibitor) and pirfenidone (unclear mechanism of action) are the only approved therapies for IPF, but have limited efficacy. The pathogenic mechanisms of this disease are not fully elucidated; however, a role for mast cells (MCs) has been postulated. OBJECTIVES: The aim of this work was to investigate a role for MCs in IPF and to understand whether nintedanib or pirfenidone could impact MC function. METHODS AND RESULTS: MCs were significantly elevated in human IPF lung and negatively correlated with baseline lung function (FVC). Importantly, MCs were positively associated with the number of fibroblast foci, which has been linked to increased mortality. Furthermore, MCs were increased in the region immediately surrounding the fibroblast foci, and co-culture studies confirmed a role for MC-fibroblast crosstalk in fibrosis. Nintedanib but not pirfenidone inhibited recombinant stem cell factor (SCF)-induced MC survival. Further evaluation of nintedanib determined that it also inhibited human fibroblast-mediated MC survival. This was likely via a direct effect on ckit (SCF receptor) since nintedanib blocked SCF-stimulated ckit phosphorylation, as well as downstream effects on MC proliferation and cytokine release. In addition, nintedanib ablated the increase in lung MCs and impacted high tissue density frequency (HDFm) in a rat bleomycin model of lung fibrosis. CONCLUSION: Nintedanib inhibits MC survival and activation and thus provides a novel additional mechanism by which this drug may exert anti-fibrotic effects in patients with IPF.
引用
- Overed-Sayer C, Miranda E, Dunmore R, et al. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Thorax. 2020. PMID: 32709610. doi:10.1136/thoraxjnl-2019-214000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。